[Determination of plasmatic beta2-microglobulin in benign and cancerous diseases (author's transl)].
The authors report on their experience of the beta2-microglobulin dosage in cancerous diseases and note an increase of its rate in 47% of the cases. A comparative study with certain benign diseases of the digestive tract shows that this dosage proves to be interesting.
D001609:Beta-Globulins / Q000032:analysis*; D002908:Chronic Disease; D003092:Colitis / Q000097:blood; D005756:Gastritis / Q000097:blood; D005767:Gastrointestinal Diseases / Q000097:blood*; D005770:Gastrointestinal Neoplasms / Q000097:blood*; D006801:Humans; D010195:Pancreatitis / Q000097:blood; D001613:beta 2-Microglobulin / Q000032:analysis*
D001609:Beta-Globulins; D001613:beta 2-Microglobulin
Intérêt de la détermination de la beta2-microglobuline plasmatique dans diverses affections néoplasiques et bénignes.